ESTRO 2025 - Abstract Book

S1298

Clinical - Lung

ESTRO 2025

With a median follow-up of 15.57 months (range 3.97-51.50m), OS obtained at 6, 12 and 18 months was 92.3%, 84.6% and 57.7% , respectively, with a LC of 100% and 90.9% at 6 and 12 months , respectively. D-PFS at 6, 12 and 24 months was 75.2%, 64.5% and 48.4% respectively. 9 patients underwent PCI (5 of them with HA) with better D PFS than non-PCI group but with no statistical significance (median D-PFS 20.67 vs 5.467, P= 0.37). Median and average PTV Volume (PTVv) were 190.82 and 246.34cm3 respectively. Differences in OS were observed between those with lower and greater-or-equal than 191cm3 PTVv, with worse OS for the second group (p=0.027). 7.7% developed acute esophagitis G3 , with better OS according to lower esophagitis grade (p=0.006) and 15.4% suffered of acute asthenia G3 . No toxicities were related to PTVv. No acute nor late G4 toxicity were detected.